Top Stories

Lupin Receives Tentative Approval from U.S. FDA for Valbenazine Capsules

Mar 28, 2023

By: BlinkX Research Team

The American Food and Drug Administration (U.S. FDA) has tentatively approved the Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, the generic version of Ingrezza® Capsules, 40 mg, 60 mg, and 80 mg from Neurocrine Biosciences, Inc., according to pharma giant Lupin Limited (Lupin). In the United States, it was estimated that Valbenazine Capsules sold for $1,235,000,000 annually. 

The global pharmaceutical business Lupin, with its headquarters in Mumbai, India, is innovation-driven. The company creates and promotes a wide variety of branded and generic formulations, biotechnology goods, and APIs in more than 100 markets throughout the Americas, Europe, the Middle East, India, and South Africa. 

The company has a strong presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health sectors and holds a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. By prescriptions, Lupin ranks as the third-largest pharmaceutical firm in the United States. In FY22, the company spent 8.7% of its revenue on research & development